{"page":{"totalFilteredElements":335},"studies":[{"active":true,"description":"COSS Register [COSSIRP]
= Klinisches Register für Kinder, Jugendliche \nund Erwachsene mit Osteosarkomen und Knochentumoren. Das COSS-Register \nbeinhaltet keine Vorgaben an Diagnostik oder Therapie. [s. Homepage der Cooperative OsteoSarkom Studiengruppe, COSS]
","eudractNumber":null,"id":948,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2005-10-01T09:42:30+02:00","shortTitle":"COSS Register - COSSIRP","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Veränderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T08:23:05+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumors

EUPAS1000000752
","eudractNumber":null,"id":11546,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-12-16T10:18:52+01:00","shortTitle":"CaboLife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumors

EUPAS1000000752
","eudractNumber":null,"id":11840,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":null,"shortTitle":"CaboLife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)","eudractNumber":null,"id":4328,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03374267 ","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-11-30T09:34:51+01:00","shortTitle":"Carat","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

A phase 2b, randomized, blinded,\nplacebo-controlled trial investigating the efficacy and safety of visugromab\nversus placebo, both in combination with pembrolizumab, pemetrexed, and\ncis-/carboplatin, in participants with newly diagnosed metastatic non-squamous\nnon-small cell lung cancer (GDFATHER-LUNG-01)

","eudractNumber":"2024-516792-32","id":10166,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07098988","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-01-14T09:32:05+01:00","shortTitle":"Catalym CTL-002-003 GDFATHER-LUNG-01","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 2b, randomized, blinded, placebo-controlled trial investigating the efficacy of visugromab plus nivolumab in combination with docetaxel versus docetaxel alone in metastatic non-squamous non-small-cell lung cancer (nsq-NSCLC) after failing one prior line of systemic treatment containing a checkpoint inhibitor for advanced/metastatic nsq-NSCLC","eudractNumber":"2024-516794-70","id":10165,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07246863","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-02-24T09:19:02+01:00","shortTitle":"Catalym CTL-002-004 GDFATHER-LUNG-02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Charakterisierung\ndes Signalnetzwerkes und der Mikroumgebung in Plasmazelldyskrasien","eudractNumber":null,"id":11386,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-02-01T09:04:26+01:00","shortTitle":"Charakterisierung des Signalnetzwerkes und der Mikroumgebung in Plasmazelldyskrasien","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Charakterisierung des onkogenen \nSignalnetzwerkes im Multiplen Myelom: Entwicklung neuer zielgerichteter \nTherapieansätze (Folgeprojekt)","eudractNumber":null,"id":2252,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2013-04-21T11:13:57+02:00","shortTitle":"Charakterisierung des onkogenen Signalnetzwerkes im Multiplen Myelom: Entwicklung neuer zielgerichteter Therapieansätze (Folgeprojekt)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung","eudractNumber":"2018-003691-12","id":5573,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"MSI (Mikrosatelitteninstabilität)","id":"mt_51"},{"name":"MSI-H","id":"mt_52"},{"name":"Mismatch Repair Deficiency (dMMR)","id":"mt_270"}],"nctNumber":"NCT04089631","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-08-07T08:25:33+02:00","shortTitle":"Circulate AIO-KRK-0217","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}